Non-ownership Filings
Positive Phase III results for Nucala in COPD | Sep. 06, 2024 |
Total Voting Rights | Sep. 02, 2024 |
EMA approval on Arexvy for 50-59 at risk | Aug. 29, 2024 |
SENKU Designation for Bepirovirsen in Japan | Aug. 28, 2024 |
Nucala approved in Japan for use in CRSwNP | Aug. 28, 2024 |
Statement: Zantac (ranitidine) litigation | Aug. 28, 2024 |
B7-H3 ADC US FDA Breakthrough Therapy Designation | Aug. 20, 2024 |
Ownership Update Filings
Director/PDMR Shareholding | Sep. 06, 2024 |
Director/PDMR Shareholding | Aug. 21, 2024 |
Director/PDMR Shareholding | Aug. 20, 2024 |
Director/PDMR Shareholding | Aug. 12, 2024 |
Director/PDMR Shareholding | Jul. 18, 2024 |
Director/PDMR Shareholding | Jul. 16, 2024 |
Director/PDMR Shareholding | Jul. 15, 2024 |